Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma

On October 15, 2018 Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported the addition of six major cancers in the United States that have adopted the amended trial protocol for the company’s registration trial in ocular melanoma liver metastases (Press release, Delcath Systems, OCT 15, 2018, View Source;p=RssLanding&cat=news&id=2371612 [SID1234529999]). These centers join Stanford Medical Center in initiating enrollment in the amended trial, giving the company wide geographic coverage in the United States. Joining Stanford Medical Center are:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Moffitt Cancer Center – Tampa, FL Center 1
Thomas Jefferson University Hospital – Philadelphia, PA
Emory University Hospital, Atlanta, GA
Methodist University Hospital, Memphis, TN
The University of Arizona Medical Center, Tucson, AZ
Ohio State University Cancer Care Center – Columbus, OH
The trial, A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma (The FOCUS Trial), is enrolling a minimum of 80 patients with ocular melanoma metastatic to the liver. The Company expects approximately 30 leading cancer centers in the U.S. and Europe to participate in the amended FOCUS Trial.

"Our team has been working diligently with participating medical centers to expedite the adoption of the new single-arm protocol," said Jennifer K. Simpson, PhD, MSN, CRNP, President and Chief Executive Officer of Delcath Systems. "These additional centers provide greater geographic coverage for this trial, which will help improve patient access. We look forward to the adoption of the amended protocol by additional centers in both the United States and Europe in the coming weeks and are working hard to achieve our goal of completing trial enrollment by the end of the first half of 2019."